Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2024 Third Quarter Conference Call. My name is Ezra, and I will be your coordinator today. If you would like to ask a question, please press star followed by one on your telephone keypad now. If you change your mind, please press star followed by two. I would like to introduce our moderator for the call, Mr. Rafael Tejada, Vice President, Investor Relations. Mr. Tejada, you may begin the call. Good morning, and thank you for joining us. On the call with me today is Marc Casper, our Chairman, President, and Chief Executive Officer, and Stephen Williamson, Senior Vice President and Chief Financial Officer. Please note this call is being webcast live and will be archived on the investor section of our website, thermofisher.com, under the heading News, Events, and Presentations until November 6th, 2024. A copy of the press release of our third quarter 2024 earnings is available in the investor section of our website under the heading Financials. So before we begin, let me briefly cover our Safe Harbor statement. Various remarks that we may make about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the company's most recent annual report on Form 10-K and subsequent quarterly report on Form 10-Q, which are on file with the SEC and available in the investor section of our website under the heading Financials, SEC Filings. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. Also, during this call, we will be referring to certain financial measures not prepared in accordance with generally accepted accounting principles or GAAP. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures is available in the press release of our third quarter 2024 earnings, and also in the investor section of our website under the heading Financials. So with that, I'll now turn the call over to Marc. Thank you, Raf. Good morning, everyone, and thanks for joining us today for our third quarter call. As you saw in our press release, we delivered another quarter of strong financial performance. We're seeing the benefit of our trusted partner status, which is resonating strongly with our customers, and we're continuing to deliver differentiated performance in the short term while further strengthening our long-term competitive position. So first, let me recap the financials. Our revenue in the quarter was $10.6 billion. Our adjusted operating income was $2.36 billion. Adjusted operating margin was 22.3%, and we delivered another quarter of strong adjusted EPS performance, achieving $5.28 per share. Our performance in the third quarter is allowing us to raise our adjusted EPS guidance once again and continues our track record of delivering differentiated results. Turning to our performance by end market. In the third quarter, underlying market conditions played out as we'd expected, and we delivered another quarter of sequential improvement and growth. Let me provide you with some additional context. Starting with pharma and biotech, we declined in the low single digits in Q3, including a five-point headwind from the runoff of vaccines and therapy revenue. This marks the third quarter in a row of sequential improvement in growth for this customer segment. Performance in the quarter was led by our Research and Safety Market Channel and our Clinical Research business. In academic and government, we grew in the low- single digits during the quarter. We delivered strong growth in our Electron Microscopy business and in our Research and Safety Market Channel. In industrial and applied, we grew in the low single digits during the quarter, highlighted by strong growth in our Electron Microscopy business. Finally, in diagnostics and healthcare, growth was flat for the quarter. As a reminder, the reported growth in this end market is impacted by the runoff of COVID-19 testing-related revenue. During the quarter, the team delivered good revenue growth in our Transplant Diagnostics and Immunodiagnostics businesses, as well as the Healthcare Market Channel. As I reflect on the end markets, underlying conditions have modestly improved each quarter as the year has progressed. This is in line with the framing we provided as part of the guidance at the beginning of the year. Let me now turn to an update on our growth strategy. As a reminder, our strategy consists of three pillars: high-impact innovation, our trusted partner status with customers, and our unparalleled commercial engine. Starting with the first pillar, it was another great quarter of innovation. First, we continue to see the impact of our innovations launched over the past couple of years. It's gratifying that our innovations continue to receive industry recognition. This is a true testament to our teams. Most recently, the R&D 100 Awards, which recognizes the most revolutionary products in science and technology, honored two of our products: our Gibco CTS Detachable Dynabeads, which launched last year, as well as our Thermo Scientific Orbitrap Astral Mass Spectrometer, which won gold in the Market Disruptor Special Recognition category as one of the most significant advancements in mass spectrometry in 15 years. Adoption of the Orbitrap Astral continues to be incredibly strong. During my customer interactions, I've had the opportunity to hear direct feedback on how significant our continued innovation is in helping our customers move science forward and advance their important work. The second part of innovation is we also had the benefit of a number of high-impact new products this quarter that we launched. To enable the development of advanced materials, we launched the Thermo Scientific Iliad Scanning Transmission Electron Microscope, which integrates a number of our advanced analytical technologies into a seamless and user-friendly workflow. This offers researchers deeper insights into the chemical nature of the most sophisticated advanced materials, down to the atomic level. The Iliad incorporates our most innovative high-resolution spectrometer to accurately determine the composition of materials, as well as our proprietary energy filter for detailed imaging and chemical analysis of samples. We recently unveiled Iliad at the European Microscopy Conference in Copenhagen, Denmark, and the feedback has been incredibly positive. Turning to innovations in life sciences, within our Biosciences business, we launched the Applied Biosystems MagMAX Sequential DNA/RNA kit, which maximizes the isolation of DNA and RNA from blood cancer samples, helping researchers identify unique insights of cancer-causing genetic alterations, and we also launched the Invitrogen Vivofectamine Delivery Solutions, a novel method for delivering nucleic acids into multiple targets with therapeutic effect, paving the way for groundbreaking new medicines. Let me give you a quick update on our progress in building on the trusted partner status that we've earned with our customers. Last month at our Investor Day, you heard us highlight this element of our growth strategy, and I'd like to bring some additional context to bring it to life. During the quarter, I had the opportunity to meet with many of our customers. As you know, we have an unparalleled customer access, and this helps us understand their near and long-term priorities. Our scale, depth of capabilities, and accumulated experience is truly resonating with customers as they rely on us to accelerate their innovation, enhance their productivity, and advance their important work. This translated into meaningful commercial wins with customers during the quarter, which speaks to the ongoing strength of our growth strategy and our ability to gain share now and in the future. I also visited China in August and spent time meeting with government officials and customers. We have strong relationships there based on our track record of positive impact and our long history in the country. Our conversations were focused on how we can collaborate to enable our customer success. I came away from the visit seeing firsthand how well positioned we are to capitalize on the market opportunities when the economy picks up in China. Let me now give you an example from the third quarter on how we advanced customer partnerships and collaborations. In our Clinical Next-Gen Sequencing business, we announced our partnership with the National Cancer Institute, a MyeloMATCH Precision Medicine Umbrella Trial. That's gonna leverage our next-generation sequencing technology to test patients for specific biomarkers so they can be matched more quickly with optimal treatments based on their unique cancer profiles. We also continue to expand our capabilities to meet our customers' current and future needs. To enhance our oral solid dose formulation capabilities for our pharma and biotech customers, we expanded our Pharma Services manufacturing footprint in Cincinnati, Ohio, and Bend, Oregon. In our Clinical Research business, we announced the expansion of our global laboratory services network with a new bioanalytical lab in Gothenburg, Sweden, which will support pharmaceutical and biotech customers with advanced laboratory services to support all phases of development, so it was an excellent quarter of advancing our growth strategy. Let me give you a quick update on the impact of our PPI business system in Q3. PPI is embedded in our culture, and there are many examples that I could share from the quarter. As always, our PPI business system and our mission-driven culture enabled our success during the quarter. PPI engages and empowers all of our colleagues to find a better way every day to enable outstanding execution. Ultimately, you see the positive impact of PPI reflected in the strong profitability and cash flow that we delivered in the quarter. During the quarter, we further enhanced our supply chain in Asia- Pacific by optimizing inventory across our network, while in Europe, we further streamlined and automated our manufacturing processes for high-end analytical instruments to meet strong demand. Now let me turn to corporate social responsibility. We have a CSR strategy that delivers competitive advantage. As a mission-driven company, we help to make the world a better place by enabling the important work of our customers. We also create a positive impact by the environment we create for our colleagues, how we support our communities, and being a good steward of our planet. Today, I just want to spend a moment on our colleagues because none of our success is possible without the work of our amazing team around the world. Our colleagues' safety is always our top priority, and the impact of Hurricane Helene was especially concerning to me, as we have about a thousand colleagues in Asheville, North Carolina, one of the hardest hit areas. In Asheville, we manufacture lab equipment and have a customer service center. I'm so grateful our colleagues there are safe. I'm also thankful for the support of our extended teams, who have provided assistance to those colleagues impacted. It's truly heartwarming, heartwarming to see how our team comes together to support each other. Turning now to capital deployment. We continue to successfully execute our disciplined capital deployment strategy to create tremendous value. We do this through a combination of strategic M&A and returning capital to our shareholders. Let me update you on our recent acquisitions. The Binding Site, now our Protein Diagnostics business, continues to perform exceptionally well. In the quarter, we achieved an IVDR claim extension in the European Union for our Optilite Freelite Mx Kappa kit. Until now, these kits have been solely used in multiple myeloma diagnostics and monitoring. The extension now allows for the product to aid in the diagnosis of neurological diseases, such as multiple sclerosis. This is an excellent example of our M&A approach, enabling a great business to be even better under our ownership, creating value for all stakeholders. As a reminder, we closed the acquisition of Olink at the beginning of the quarter. The integration is progressing smoothly. The business is well positioned for a bright future. As you heard at our Investor Day, we're excited by the role we're playing in advancing proteomics research. As I reflect on the quarter, I'm proud of what our team's accomplished and grateful for their contributions to our success. Let me now turn to our guidance. Given our strong performance in the third quarter, we're raising our adjusted EPS guidance, which we now expect to be in the range of $21.35-$22.07. And we continue to expect revenue to be in the range of $42.4 billion-$43.3 billion. Stephen will take you through the details in his remarks. So to summarize our key takeaways from Q3: we delivered another strong quarter of financial results, driven by our proven growth strategy and PPI business system. We continue to enable our customers' success, and this reinforces our trusted partner status and industry leadership. Our growth has been steadily increasing as we've gone through 2024, and we once again have raised our adjusted EPS guidance for the year. We're well positioned to deliver differentiated performance in 2024, as we continue to create value for all of our stakeholders and build an even brighter future for our company. With that, I'll now hand the call over to our CFO, Stephen Williamson. Stephen? Thanks, Marc, and good morning, everyone. I'll take you through an overview of our third quarter results for the total company, then provide color on our four business segments, and I'll conclude by providing our updated 2024 guidance. Before I get into the details of our financial performance, let me provide you with a high-level view on how the third quarter played out versus what we'd assumed for Q3 in the midpoint of our prior guide. On the top line, both organic revenue growth and core organic revenue growth increased sequentially for the third consecutive quarter. Revenue was largely in line with what we'd assumed for Q3 in the midpoint of our prior guide. Turning to the bottom line, adjusted EPS was $0.06 ahead of what we'd assumed in the prior guide for Q3. That was a net impact of the following: $0.02 of strong operational performance, $0.06 of lower net interest cost due to favorable timing of cash flow generation and more favorable rates than had been assumed. These are partially offset by an additional $0.02 of FX headwind versus the assumption for the quarter. We're also executing well in free cash flow generation. Year-to-date, free cash flow is 22% higher than the same period last year. So we had another strong quarter and are well positioned to deliver differentiated financial performance in 2024. Let me now provide you with some additional details on Q3. Beginning with earnings per share, and in the quarter, adjusted EPS was $5.28. GAAP EPS in the quarter was $4.25. On the top line, Q3 reported revenue, organic revenue, and core organic revenue were all flat on a year-over-year basis. In the quarter, pandemic-related revenue was approximately $100 million. This was largely from vaccines and therapies. This represents a 3% headwind to organic revenue growth. Turning to our organic revenue performance by geography, in Q3, North America declined low- single digits, and Europe, Asia- Pacific, and China within Asia- Pacific were all flat year- over- year. With respect to our operational performance, we delivered $2.36 billion of adjusted operating income in the quarter, and adjusted operating margin was 22.3%, 190 basis points lower than Q3 last year, slightly ahead of our expectations for the quarter. Total company adjusted gross margin in the quarter came in at 41.8%, 20 basis points lower than Q3 last year. In the quarter, we continued to deliver strong productivity, reflecting our continued focus on cost management. This enabled us to fund strategic investments to further advance our industry leadership and partially offset the expected impact of unfavorable mix this quarter. Moving on to the details of the P&L, adjusted SG&A in the quarter was 16.2% of revenue. Total R&D expense was $346 million in Q3, reflecting our ongoing investments in high-impact innovation. R&D, as a percent of manufacturing revenue, was 7.3% in the quarter. Looking at our results below the line, our Q3 net interest expense was $80 million, which is $33 million lower than Q3 2023 due to higher cash balances and short-term investments. Our adjusted tax rate in the quarter was 10.5%, and average diluted shares were 384 million in Q3, approximately 4 million lower year- over- year, driven by share repurchases net of option dilution. Turning to free cash flow on the balance sheet, year-to-date free cash flow from operations was $5.4 billion. Year-to-date free cash flow was $4.5 billion, and after investing $880 million of net capital expenditures. During the quarter, we deployed $3.1 billion of capital through the acquisition of Olink, and we ended the quarter with $6.6 billion in cash and short-term investments, and $35.3 billion of total debt. Our leverage ratio at the end of the quarter was 3.3 x debt to adjusted EBITDA, and 2.7 x on a net- debt basis. In concluding my comments on our total company performance, adjusted ROIC was 11.4%, reflecting the strong returns on investment that we're generating across the company. Now I'll provide some color on our performance of our four business segments, starting with Life Sciences Solutions. Q3 reported revenue in this segment declined 2%, and organic revenue was 4% lower than the prior year quarter. Growth in this segment was driven by the impact of the pandemic. Q3 adjusted operating income for Life Sciences Solutions decreased 3%, and adjusted operating margin was 35.4%, down 50 basis points versus the prior year quarter. During Q3, we delivered strong productivity, which is more than offset by unfavorable volume mix, retention costs related to the Olink acquisition, and strategic investment. In the Analytical Instruments segment, both reported revenue and organic revenue grew 3% versus the prior year quarter. We continue to deliver very strong growth in our Electron Microscopy business. In this segment, Q3 adjusted operating income decreased 4%, and adjusted operating margin was 24.9%, 180 basis points lower year- over- year. In the quarter, we delivered strong productivity, which is more than offset by unfavorable mix and strategic investments. Turn to our Specialty Diagnostics segments in Q3, both reported revenue and organic revenue grew 4% versus the prior year quarter. In Q3, we delivered strong growth and are led by our Healthcare Market Channel and our Immunodiagnostics and Transplant Diagnostics businesses. Q3 adjusted operating income for Specialty Diagnostics increased 3%, and adjusted operating margin was 25.9%, 20 basis points lower than Q3 2023, and during the quarter, we delivered good productivity, which is more than offset by strategic investments, and finally, in Laboratory Products and Biopharma Services segment, both reported revenue and organic revenue were flat versus the prior year quarter. Organic growth in this segment was led by our Research and Safety Market Channel. The runoff of vaccines and therapies revenue had a mid-single-digit impact on the growth in this segment in Q3, and this was offset by very good underlying growth in our Clinical Research and Pharma Services businesses. As expected, Q3 adjusted operating income declined 18% and adjusted operating margin was 13.5%, which is 290 basis points lower than Q3 2023. In the quarter, we delivered strong productivity, which is more than offset by the expected unfavorable mix and strategic investment. Turning now to guidance, as Marc outlined, our strong performance in Q3, we're raising our 2024 full year adjusted EPS guidance. We now expect adjusted EPS to be in the range of $21.35-$22.07, which is a $0.03 increase at the midpoint. As we've done in the past two quarters, at the midpoint, we've banked half of the Q3 beat and maintained the remainder as additional cushion for Q4. Revenue guidance continues to be in the range of $42.4 billion-$43.3 billion, and we continue to assume that core organic revenue growth will be in the range of -1% to +1% for 2024. We also continue to assume that the market decline is low- single digits this year. Our proven growth strategy and PPI business system execution is once again enabling us to take share. Our updated 2024 guidance continues to assume an adjusted operating income margin between 22.5% and 22.8%. We now expect net interest costs to be in the range of $340 million-$380 million for the year. Another strong quarter, enabling an increase in the guidance outlook for the year. We remain well positioned to continue to deliver differentiated performance. It'd be helpful to remind you of some of the key underlying assumptions behind the guide that remain unchanged from the previous guidance. In 2024, we're assuming just under $100 million of testing revenue and between $300 million-$400 million of vaccines and therapies related revenue. In total, this represents a year-over-year headwind of $1.3 billion-$1.4 billion, or 3% of revenue. We continue to expect the adjusted income tax rate will be 10.5% in 2024, and for the year, we're assuming between $1.3 billion and $1.5 billion in net capital expenditures and free cash flow in the range of $6.5 billion-$7 billion. In terms of capital deployment, we're assuming $3 billion of share buybacks, which were already completed in January. We returned $600 million of capital to shareholders this year through dividends, and in Q3, we deployed $3.1 billion to acquire Olink. Full year average diluted share count is assumed to be approximately 383 million shares. And finally, as you think about the outlook for the year, you should consider the midpoint of our guidance range as the current view of the most likely outcome for the year. Implied in that midpoint is Q4 revenue of $11.3 billion and adjusted EPS of $5.96. That would reflect 2.5% organic revenue growth for the fourth quarter, which is unchanged from the previous guidance, and is a continuation of our sequential increase in growth that we delivered each quarter throughout the year. And as a reminder, Q4 organic revenue growth has the benefit of two extra selling days, which equates to approximately 1% and a headwind from vaccines and therapies of approximately 2.5%. To conclude, we had another strong quarter, and we're well positioned to deliver differentiated performance for all of our stakeholders in 2024. With that, I'll turn the call back over to Raf. Thank you, Stephen. Operator, we're ready for the Q&A portion of the call. Thank you very much. If you would like to ask a question, please press star, followed by one on your telephone keypad now. If you change your mind, please press star followed by two. In order to allow everyone in the queue an opportunity to address the Thermo Fisher management team, please limit your time on the call to one question and only one follow-up. If you have additional questions, please return to the queue. Our first question comes from Michael Ryskin with Bank of America. Michael, your line is now open. Please go ahead. Great. Thank you, and thanks for taking the question. Marc, maybe kick things off with you. You talked a number of times during the prepared remarks about some sequential improvement as the year has gone on, and I think the view is that'll continue into 4Q and into 2025. It looks like this continues to be a very gradual recovery, just a very slight step up in market conditions as we go through the year. You know, no major changes, no step function change. Do you expect that pace of recovery to continue into the next quarter and into 2025? Or do you think there could be an inflection at some point over the next, you know, 2-4 quarters where things accelerate a little bit? I guess, put another way, sort of what's holding the market back from a faster snapback? Yeah, Mike, thanks for the question, good morning, so what I thought I'd do is maybe actually put some framing comments overall, then I'll get to your 2025 question, as well, so you know, for the Q&A session today, as I think about the third quarter, as we sit here in October, and how the year has progressed, you know, first, it was a good quarter, and the market conditions have been in line with our expectations, and they've been modestly improving as we progress through the year, which is what we expected to happen, so it's good that that's playing out that way. In Q3, for us, organic growth was flat. We were able to offset a three-point headwind from the runoff of COVID-19 related revenues, so it puts it in context of how we're performing. You know, each quarter, our organic growth has improved, as the year has progressed, and I'm really quite excited by the fact that we're expecting the fourth quarter to return to growth organically, which is a good thing. Operationally, you know, we're executing our proven growth strategy. We have strong financial management, that's been able to allow us to increase our adjusted EPS guidance, each quarter and kind of make all of this a non-event in terms of performance. So all of that is kind of the framing for the discussion today. So when I think about 2025, and I'll kind of just kind of boil it all together into sort of how do I think about the year, you know, the first thing is, you know, from our perspective, you know, the best time to provide guidance is on our Q4 2024 call, which is in January. You know, at that point, we're going to have the latest view of the market and the macro conditions and how ultimately we finish the year. And what we're going to approach it as the same as we did in 2024. We're going to give you our best thinking for the year ahead, and then execute against it. From my own perspective, and personally, you know, I'm excited for 2025, right? And as I think about it in October, you know, the end markets are modestly improving throughout the year. You know, we're excited that in the fourth quarter we're going to return to growth organically. For us, in 2025, what I would say is that it's the final year of the runoff of the pandemic-related activity, and while that'll still be a headwind to growth, it's going to be less than it was in 2024. And then I always think about how we're performing, right? And as a company, we're executing well. You know, our growth strategy is driving share gain. Our PPI business system enables outstanding execution. You know, we have a disciplined capital deployment strategy that generates returns. Our acquisitions are performing well, and, you know, we're going to be well positioned to deliver differentiated performance once again in 2025. We'll look forward to updating you on that in January as we have the best view of what the environment is. Okay. All right. Thanks, I appreciate that. I guess for my follow-up, maybe we'll want to dig a little bit into pharma and biotech as a customer group. You know, you talked about a low- single-digit decline, and obviously there's a headwind there from the COVID-19 runoff as well. But any additional color you can give on how that segment is performing, whether between larger pharma or smaller biotech, whether it's between the some of the reagent and businesses and Biosciences versus the the Clinical Trial business or the Pharma Services business. Just that's been a focus point for investors, and we'd love to get some color on that. So you're going to get a lot of fan mail from your peers on this call, sort of asking each of all the questions within pharma and biotech. I'll take a high-level shot at it. First, when I think about the third quarter and how things progressed, you're seeing a sequential improvement, which is good. When I think about underlying performance, right, we obviously had, you know, a mid-single-digit headwind from the pandemic runoff. You're seeing that the conditions continue to improve. You know, in aggregate, obviously, they're somewhat muted because they're below the long-term expectations for the market growth, right? That's nothing surprising. Where the positives are, you know, and sort of the data points as we sit here, you know, confidence in biotech is improving. Funding in biotech in the industry has been modestly improving as the year progresses, so it's definitely meaningfully better than it was in 2023, and when I think about, you know, the large pharma, in a way, I think it's kind of normal distribution amongst the different companies. Some doing, you know, extraordinarily well, others, you know, adjusting to how their pipelines are performing. And, you know, customers have been adjusting to the IRA, and, you know, you see that in a more muted growth environment. But we're obviously incredibly well-positioned with this customer base, and we're clearly delivering differentiated performance relative to others. So, the trusted partner status, our unique value proposition, these things resonate. So, we feel good about the long-term health of pharma and biotech and how we're performing this year. Thanks, Mike. Thank you. Thank you. Our next question is from Rachel Vatnsdal, analyst with JP Morgan. Rachel, your line is now open. Please go ahead. Great, thank you. Thanks for taking the questions, you guys. First up, on the CRO, maybe following up on some of your comments there about pharma versus biotech, but really specifically looking at PPD here. Could you give us an update on how much of PPD is indexed to large pharma customers versus biotech? And did you see any differences in trends across the two customer types this quarter within PPD? And then, as a follow-up, some of your peers in the CRO sector have started to create some noise around their outlooks on 2025 and what that recovery looks like. So for Thermo, if PPD is more or less, let's call it a mid-single-digit business this year, and normal is 8% for PPD, how are you thinking about the pace of recovery for PPD into 2025? So, Rachel, thanks for the question. Good morning. When I think about our Clinical Research business, actually, you know, it's performing well. When I think about, you know, the business, you know, delivered growth in the quarter, it obviously has a meaningful, you know, headwind from the runoff of vaccines and therapies, you know, CRO-related activity. So, from that perspective, I feel good about how we're doing. Next quarter, I'm gonna really spend some time talking about the magic that we're unlocking on the combination between our Pharma Services and our Clinical Research business, and how that really adds differentiated value for our customers in terms of performance. So I wanna focus on that one. We just announced how we talk about that to our customers. We've been doing this for quite some time, and it's really been quite spectacular, so our momentum with the customer base is quite good, and we're executing well. When I think about, the, you know, our position, we have a slightly larger position serving biotech more broadly than we do serving pharma within Clinical Research, in terms of the mix of the business, but both customer sets are very important, and when I think about, some of the highlights, you know, the biotech customers more quickly adopt that unified set of capabilities 'cause it's easier for them, just organizationally, to leverage all of pulling everything together once, so you're seeing that, in authorizations and momentum, and biotech is particularly moving in the right direction, so that's how we see it. You know, in terms of the 2025 and long-term 8%, all these things. You know, we don't, as you know, we're gonna give our views on 2025 next year. And we don't guide down to the business unit performance within the company, but we'll give the puts and takes of what's growing faster and what's growing at the average and what's growing more slowly than the average when we get to the guidance next year. Understood. And then on my second question, just around Life Science Solutions. So growth was a little softer than what the street was looking for this quarter for that segment. You know, we've heard from a few of your bioprocessing peers that pointed towards solid trends in 3Q. So can you unpack for us the performance within that Life Science Solutions segment? How did bioproduction versus Biosciences and genetic sciences trend in the quarter? And, you know, what, if anything, fell below your expectations there? Yeah, Rachel, thanks for the question, and thank you for the framing of the question, because actually, the numbers are different than what seems to have been modeled in the analyst models, but actually, the business performed in line with our expectations for the quarter. So when I think about what happened in the quarter, in the third quarter, we had our largest impact of the COVID roll-off in this segment. That's something we knew, something. That's why it came in line with our expectations relative to the other quarters. Q3 was the most difficult comparison in the COVID-related activities for us, so that probably explains a little bit of the modeling difference. In terms of how our business is performing, you know, bioproduction is certainly the one that gets the most, you know, interest because there are a number of companies that are just bioproduction companies that have stocks out there. Actually, the quarter played out as we expected. It was nice to see, you know, strong momentum in orders, both sequentially and year- over- year. Revenue continues to progress in the right direction sequentially, in terms of growth. And that obviously is going to be, you know, less of a headwind going forward and ultimately gonna be a tailwind in the not-distant future in terms of bioproduction. That's good. The only other commentary I would make on the LSS segment, it's not an enormous business, but our Clinical Sequencing business is doing really well, right? You see the announcements. I talked about one of them with the National Cancer Institute. You saw after the quarter end an announcement from one of our customers in terms of, you know, companion diagnostic approved using our sequencing for brain cancer. These are really positives in terms of customers applying our technology to make a huge difference on patient lives and the course of treatment. So that business is doing quite well. Thank you, Rachel. Our next question is from Jack Meehan with Nephron Research. Jack, your line is now open. Please go ahead. Thank you. Good morning. Morning. Maybe for Marc, I hate to ask a question about month-by-month dynamics, but could you just talk a little bit more about how the quarter played out? The reason I ask is, you know, core organic growth was flat. I think the street was looking for 1%, so technically missed that. And, you know, I always assume there's some conservatism embedded. So I was just curious, like, did September fall short for some reason? If so, why? I know you talked about the hurricane, but just any color on kinda how the quarter played out would be great. Yeah. So Jack, in terms of the growth, it was largely in line with what we expected to happen for the quarter. So from that perspective, you know, versus the external models, I always think, you know, there's, you know, degree of accuracy between the street and, and what we say. We try to give as clear as we can on these calls about what our expectations are for the, for the year and the upcoming quarter. And I think, you know, Stephen gave some very clear, you know, views, again, this quarter about the next one. So, you know, from our perspective, kind of played out as, we thought. In terms of the pacing through the quarter, largely as we expected, I would say, at the very, very end of the quarter, academic and government wasn't quite as strong as you normally would see, but, like, in the scale of our company, like, you know, in a $10.5 billion+ quarter, that's, you know, $10 million-$20 million. It's not a big number, but so I didn't really jump out- Mm-hmm with any patterns, of any significance in terms of how the months played out during the quarter. Got it. Okay. And then for Stephen, you know, on guidance, you still have a $900 million range from the bottom to the top end. I know you're pointing us to the midpoint here, but was there any consideration in narrowing it? What's the real level of variability in the business? Yeah, Jack. So for simplicity, we kept the range in our guidance from the last time round, and as you said, I encourage you to not overthink it, just focus on the midpoint. That's the kinda current view of where we most likely outcome for the quarter as we see it right now. And other than macro events, you know, the largest swing factor for Q4 is likely to be the level of year-end spend by our customers. Thanks, Jack. Okay. Thank you, Stephen. Thanks. Our next question is from Doug Schenkel with Wolfe Research. Doug, your line is now open. Please go ahead. All right, thank you, and good morning, Mark and Stephen. As we sit here nine months, you know, well, 10 months into the year with nine months of financials in the books, you know, the portfolio does seem to be tracking the plan. You know, that said, there are always puts and takes on what's working better or worse than original target. As we sit here today, what geographies, customer groups, product categories, however you want to frame it, what's tracking ahead of expectation, what's below expectation? And as you think about the next few quarters, would you expect things to normalize back to what you were targeting at the beginning of the year, or, you know, are there seemingly some, you know, more durable changes to, you know, how things are coming together? I ask, you know, not just to look back, but also just as kinda we're thinking about, you know, exit rates looking ahead to 2025. So, Doug, thanks for the question. So if we go back to January, and we say, you know, we had a set of expectations for the year, and those expectations have really played out with an incredible degree of precision so far through the first nine months. First quarter on revenue was a little bit higher. The next two quarters were super tight around what we expected, and we're looking forward to the fourth quarter, where we return to growth. And when you unpack the different businesses, there's actually not a lot there in terms of them also performing differently than what we expected, and I'll come back to that with a couple of other things. But so there was not like something is meaningfully different than what we thought in January, better or worse. The two things we did talk about, about what we could change the range for this year was: how would biotech perform in terms of funding, and what would happen in China, right? And biotech is progressing in the right direction. Funding is improving, confidence is improving. As you know, there's a lag between funding and ultimately how that flows into our industry. So that's encouraging, relative to what we saw certainly in the previous couple of years in that dimension. So that kinda helps you think a little bit about market conditions going forward. The second was China. China has not progressed, right, in terms of economic activity. It's been incredibly muted in terms of the environment. The government did announce two different types of stimulus programs. Actually, interestingly enough. First, that affect our industry in a positive way, which is around the equipment stimulus and the loan program that they have for their customers or their institutions. And we expect that's largely a 2025 impact and beyond. So that's encouraging. And more recently, they actually announced stimulus programs to spur economic growth and business confidence and consumer confidence, that actually would also be helpful for the longer term there. So that one is more on the come, right? Because it hasn't, you know, the words have said, but, you know, in terms of the impact yet to the economy, it hasn't been seen. So that'll be a swing factor, going forward and on how that plays out. And then in terms within our businesses, probably the only thing that I would really call out is, it really is awesome to see the adoption of our high-end technologies and analytical instruments, right? It's just it's amazing how, you know, customers, even though what is obviously a muted environment in total, right? We know the industry is declining this year, and that's nothing of a surprise. You know, that business is just getting great adoption for our technologies. And it was one of the cool things we said during the pandemic, when we were just really driving great growth because of our response, we reinvested in R&D, and that reinvestment has really led to differential performance in terms of how our technology has been adopted. So I'd call that out. Is that massively different than what we expected in January? No, but it's great to see, and it's a little bit better than what we expected, and the offsets to that are immaterial across the rest of the company. Thanks for all that, Marc. I think my follow-up is probably a Stephen question, but obviously welcome, you know, either of you, as always, to chime in. You know, as I look at our model, I'm reminded that, you know, from 2022-2024, your core growth will have been, you know, about 0%, down about 5%, and, you know, about flat again this year, you know, year- by- year. So in a period where revenue growth has been challenging, you know, you've actually maintained operating margin at similar levels for, you know, two years in a row, assuming you meet guidance this year. So as growth starts to improve slowly but surely into next year, is it fair to assume that there could be outsized margin improvement and incremental margin generation? You know, essentially the benefit of, of strong operating discipline through a challenging period. I guess I'm just wondering if margin expansion gets back into the LRP range before revenue does. Yeah. So, Doug, thanks for the question. So, just to frame up how we think about the long-term financials. So, for us, long-term, 7%-9% top line growth enables 40-50 basis points of expansion. So that's kind of how we think about the future. And then you get down to the near term and could it be slightly higher? I think I've said in the past that certain aspects of our business where volumes have been more challenged, and we've appropriately addressed the cost base, that there's some incremental benefit that can come from the return to volumes in those businesses. So there's an aspect of this that could be slightly higher. As we get into the next year and give guidance in January, we'll be able to frame up kind of how we think about the world, what's the level of that top line growth, and then what's an appropriate level of margin expansion. And there's always a trade-off between making sure we get good profitability for our shareholders and then appropriately investing in the business as we think about going forward. So that kind of frames it up, and look forward to getting into the details on the next call. Thanks, Doug. All right. Thanks, guys. Our next question is from Tycho Peterson with Jefferies. Tycho, your line is now open. Please go ahead. Hey, thanks. Marc, I wonder if you can just touch a little bit more on some of the drivers in LPS. You know, you talked about, obviously, the channel, the safety, and the market channel. But, curious, you know, we've heard more about share gains for Fisher, so I'm curious if you can kinda comment on that dynamic. And then, you didn't call out PPD and Patheon, you know, within your comments specifically on that. I'm just wondering if they were actually up in the quarter. You want to start, Stephen? Yeah, yeah, Tycho. So in my prepared remarks, I did talk about the dynamic where, when you think about the underlying growth in both Pharma Services and Clinical Research, it that offset the significant pandemic headwinds. So from an organic growth standpoint, you know, that's kind of a net neutral. But when I think about what the underlying growth is there, it's strong. Anything else, Marc, in terms of color? No, the channel is doing really well. Actually, both the Healthcare Market Channel and the Research and Safety Market Channel continue to do well. They, they're delivering nice growth and actually winning some really nice customers, which bodes well for the future. So that part of the commentary that I talked about customer wins and those things in my remarks, really, you know, number of our businesses. But in those comments are really around large wins, and channel clearly had some nice ones during the quarter, which doesn't show up at all in revenue in the quarter that you win them, but over the coming quarters ahead, it really is quite a positive. Okay. And then I guess the follow-up, just on the margins for the lab products and services. Obviously, you had the vaccine and therapy runoff. You know, is there anything you're willing to comment around price in this environment? You know, the ability to potentially take more, or are you giving more as you, you know, try to grab more CRO and CDMO work? And then how are you also thinking about capacity expansion for Patheon? Obviously, we saw Novo offload one of the Catalent facilities in Europe. I'm just curious how you're thinking about, you know, as more capacity comes to market, both, you know, from Novo and Catalent, but also WuXi AppTec, how interesting that might be for you. You want to talk about price and aggregate, and I- Yeah, pricing in aggregate for the company, we were just over 1% in price for the quarter, so still ahead of the kind of normal run rate that we see as kind of, you know, 0.5% - 1% price on net basis across the whole company, so a trend that's similar to what we've seen for the, you know, first three quarters of the year. It's been consistent. Yeah, I'd say probably the pricing environment is back to normal. It's a good industry. You know, price goes up modestly each year. You had the dynamic inflation, where price went up certainly more than what is usual, and we're kind of back to the normal dynamic. In terms of our Pharma Services business capacity expansions, you know, as everyone knows, we've expanded our investments in sterile fill-finish capacity, and have, you know, a number of lines that are coming online, if you will, during the course of 2025 and 2026 to support customer demand. So that's a positive that does put pressure on margins in the short term, because there's costs in training and getting the qualification process for the facilities. But certainly, as we get through 2025, you know, you'll see higher levels of utilization on that capacity to support the strong growth in sterile fill-finish. And so that's the dynamic there. As I announced in my remarks, because of these specific capabilities of interest in oral solid dose, which is not our biggest part of our offering in drug products, we did do some capacity expansions in Bend, Oregon and Cincinnati, Ohio, to meet the customer demand, which is good on the development side of the equation. So that's the dynamic there. Okay. Thank you. Thanks, Tycho. Our next question is from Matt Sykes with Goldman Sachs. Matt, your line is now open. Please go ahead. Analytical Instrument segment. You've shown pretty consistent growth in what has been a, I would call, a challenging environment. I know that Astral and microscopy have been big drivers of that. If you strip those two out and just look at the rest of your instrument categories, could you maybe talk about what demand looks like from them in those instrument categories from the biopharma side, as well as other customers? And do you sense any kind of replacement cycle kicking in for some of those instruments as we move into 2025? Just any thoughts on that would be great. Yeah, Matt, thanks for the question. So when I think about Analytical Instruments, you know, we had 3% organic growth in the quarter. You know, playing out as we expected, obviously, innovation really matters. You know, for us, you know, we've been able to launch a number of products that have been adopted. Actually, you know, on the high end, we talk about Iliad in this particular quarter, that bodes well to continue to drive momentum, electron microscopy. Obviously, Astral has done very well, as you noted. Stellar, which we launched last quarter, the early interest is quite strong, and so those things are going well. Inuvion, which is ion chromatography, more of a mid-range technology, very important in that particular category of chromatography, incredibly strong demand. So our innovation has been well adopted. You know, when you take out all of those things, you just kind of say the routine capital equipment aspects of instruments. You know, actually, pretty muted conditions, right? Nothing surprising. You know, when we talk about for the full year, for the whole company to have market down, you know, in the low- single digits, you would expect capital equipment to have muted conditions. They are. And a big driver of that, obviously, is China, which is in instrument businesses for the whole industry, is a large portion of demand, and obviously, that market is most challenged. So, exactly where we are in the replacement cycle for those things, I think it really varies by, you know, by customer, by product type, and all of that, and we didn't see any particular pattern that jumped out to indicate any change in trajectory. Got it. Thanks. And then, Stephen, just a modeling question for you. Just the implied Q4 operating margin looks like over a 100 basis points step up to get to that full year guide. Understand there's a return to growth expectation on the top line, some, probably some gross margin leverage. Was there anything on the cost-saving sides or mix that we should be aware of driving that step up in margins for the Q4? Yeah. So for Q4, the kind of the midpoint of that guide is a 50 basis points increase year- over- year for the quarter, and, that's in line with when I think about the margin profile. It's really the step up in the level of revenue and kind of the seasonality to our revenue profile. So it kind of logically makes sense when you look at it sequentially in terms of the change. Okay. Thank you. Great. Thanks, Matt. Operator, we will take one more question. Yeah. Our next question is from Dan Brennan with TD Cowen. Dan, your line is now open. Please go ahead. Great. Thanks. Thanks for the questions. Maybe, Marc, just on pharma R&D, you know, headlines have been mixed, but, you know, we just looked at, like, a global analysis of R&D trends, and actually they look pretty good for large pharma, up nearly 8% and kind of global pharma, up like mid-5%. So I'm just wondering, like, kind of square the circle with kind of the, you know, the weaker end market growth that you've kind of based your guide on, and, you know, maybe why we're not seeing what appears to be a decent level of R&D growth here, not translating into better revenues. Is like, has anything changed? Maybe is there more dollars going to service, inflation, or just in terms of the traditional amount of dollars that you know, your business would see from R&D? Is anything kind of different this time? Yeah, I think one element is significant investment by our customers in AI. Not Analytical Instruments, unfortunately, but when I think about generative AI and where they're spending on technology, there's a significant piece to that, so you need to factor that in. Yeah, so Dan, probably the when we think about pharma and biotech, right, it covers the full spectrum of activity, and one of the things within that is bioproduction, you have the headwinds across the industry of bioproduction, right, so you know, there's not like an R&D specific call-out that you can derive from the numbers. We all understand the, you know, the runoff on the pandemic is largely in the Clinical Research side and largely in the Bioproduction and Pharma Services side, so that's a little bit of what's muting the growth in total for our industry. In terms of the dialogue that I've had with customers and sort of what's the tone, people are super excited by the pipeline. Like, you know, whether it's the fact of the GLP-1s and the scale of a high-impact medicine, that it just really is getting people excited. But, you know, there's really interesting work going on Alzheimer's, which is fantastic, and, you've seen some interesting approvals in other neurological, diseases that, you know, there's just a lot of excitement about pipelines and opportunities. And so I believe that, you know, the, the data you're quoting about the R&D investments looking good reflects that customers have optimism for the future, and ultimately that's going to translate into our space. So, which is why we're so confident about the long-term prospects for our industry. Great, thanks for that. And then maybe just one follow-up on China. A few peers have discussed that they're seeing a pause in instrument spending ahead of the stimulus next year. I think you mentioned in a prior question how, like, China instrument demand is kind of a weaker spot. Any color there? And, you know, as the stimulus comes through, like, is this going to be a meaningful lift for you guys in 2025, or you think it'll be more modest? Thanks a lot. Dan, thanks. So when I think about China, and I think about stimulus, certainly a discussion I had when I was meeting with government officials and certainly with customers as well, really, activity has been around, you know, applying for the funding, right? And going through that process. So there's been quite a bit of that activity. So I, I'm not sure that that traded something else off, but it might have. Like, I don't know. Like, none of the customers specifically mentioned it, but I didn't ask the question that way. I was much more interested about how are they tapping into the available new funds and how are they thinking about it. And, you know, there seemed to be, you know, optimism and enthusiasm for the upcoming investment. So I think stimulus will be a 2025 activity, you know, maybe a little bit in Q4. Probably not all that significant, but. That's how I think about what's going on in China. The other thing from the China trip was that I came away with, and obviously I knew it going in, but, you know, we are incredibly well positioned in the country. I mean, we have deep relationships with our customers, very strong earned relationships with government. You know, being a scale player for 40 years in the country and supporting, you know, their response to the pandemic, various, you know, crises in the past, as just a good local participant to help society out there, we benefit from that, and we're well positioned to help our customers. And we had great discussions about customer dialogue with where we can collaborate and how we can help them, you know, have the Chinese population be healthier through our technologies. So I think, you know, as the economy improves there, we're going to be well positioned to capitalize on that. So thank you for the questions today. Let me just make a quick closing comment. And, you know, it's good to have another strong quarter behind us, and we're very well positioned to deliver differentiated performance into 2024, you know, as we continue to create value for all of our stakeholders and to build an even brighter future for our company. We look forward to updating you on our fourth quarter and full year performance in our January call. And as always, thank you for your support of Thermo Fisher Scientific. Thanks, everyone. Thank you very much, everyone, for joining today's call. You may now disconnect your lines.